BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

12 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy.EBI
Fudan University
Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds.EBI
Fudan University
Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor.EBI
Fudan University
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.EBI
Sichuan University
Targeting EGFR degradation by autophagosome degraders.EBI
Jinan University
Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).EBI
East China University of Science and Technology
Targeted Degradation of Alpha-Synuclein by Autophagosome-Anchoring Chimera Peptides.EBI
Sun Yat-Sen University
The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.EBI
Aligarh Muslim University
Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT).EBI
Second Military Medical University
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.EBI
Goethe-University Frankfurt
LSD1 inhibitors and medical uses thereofBDB
Constellation Pharmaceuticals